Zymeworks (ZYME) closed at $28.85 on October 27, 2026, up 1.7% from the previous close, on volume of 1,064,863 shares (30-day average 1,157,696).
Data as of October 27, 2026.
27-Oct-2026
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Wed, 28-Oct 1:20 AM ET)
Business Wire (Tue, 27-Oct 7:00 AM ET)
Stifel Nicolaus Keeps Their Buy Rating on Zymeworks (ZYME)
TipRanks (Mon, 26-Oct 10:38 AM ET)
Zymeworks early-stage results on ADC show anti-tumor activity in ovarian cancer
Seeking Alpha News (Sat, 24-Oct 2:03 PM ET)
Globe Newswire (Sat, 24-Oct 2:30 AM ET)
TipRanks (Fri, 23-Oct 2:45 PM ET)
Zymeworks Announces Global DLL3 T-Cell Engager Partnership
TipRanks (Fri, 23-Oct 6:29 AM ET)
Globe Newswire (Fri, 23-Oct 6:00 AM ET)
Globe Newswire (Mon, 19-Oct 6:00 AM ET)
Globe Newswire (Thu, 15-Oct 6:00 AM ET)
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Zymeworks trades on the NASDAQ stock market under the symbol ZYME.
As of October 27, 2026, ZYME stock price climbed to $28.85 with 1,064,863 million shares trading.
ZYME has a beta of 0.26, meaning it tends to be less sensitive to market movements. ZYME has a correlation of 0.00 to the broad based SPY ETF.
ZYME has a market cap of $2.07 billion. This is considered a Mid Cap stock.
Last quarter Zymeworks reported $5 million in Revenue and -$.62 earnings per share. This fell short of revenue expectation by $-14 million and missed earnings estimates by -$.22.
In the last 3 years, ZYME traded as high as $31.34 and as low as $6.51.
The top ETF exchange traded funds that ZYME belongs to (by Net Assets): VTI, IWM, IBB, IWO, DFAS.
ZYME has outperformed the market in the last year with a price return of +62.6% while the SPY ETF gained +14.8%. ZYME has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +26.2% and +13.9%, respectively, while the SPY returned +4.4% and -1.1%, respectively.
ZYME support price is $27.54 and resistance is $29.20 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ZYME shares will trade within this expected range on the day.